IRVINE, Calif.—ChromaDex signed a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.
The collaboration between ChromaDex and St. Jude will focus on screening ChromaDex's natural product libraries against certain biological assays and tumor models with the intent of identifying high-value, potentially patentable natural products for specific therapeutic indications.
Under the terms of the agreement, ChromaDex will be responsible for providing the natural product libraries for screening, as well as the natural product chemistry expertise to continue the development of any identified candidates into commercial opportunities. St. Jude will screen the natural product libraries provided by ChromaDex, as well as perform other chemical assays to further the characterization of the compounds provided.
"St. Jude is a pioneer in the development of therapies to fight pediatric catastrophic diseases, and with this partnership, we will work to help support their important work," said Frank Jaksch Jr., founder and CEO of ChromaDex. "The ChromaDex catalog offers thousands of unique phytochemical compounds, many of which have never been investigated for their therapeutic potentials. We are excited to start this collaboration with St. Jude, as this program will not only allow ChromaDex to extract value from the natural products library, but also advance pediatric disease research."
ChromaDex also recently launched the first and only commercially available nicotinamide riboside (NR), which links to several health benefits like weight management, anti-aging and cardiovascular health.